Literature DB >> 10536169

Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3.

F K Guerra-Vladusic1, G Scott, V Weaver, E A Vladusic, M S Tsai, C C Benz, R Lupu.   

Abstract

We have previously reported that Heregulin (HRG)/neu differentiation factor (NDF) induced growth arrest and cellular differentiation in breast cancer cells overexpressing erbB-2 receptor. To elucidate the cellular mechanisms underlying the growth inhibition by HRG, we developed an in vitro model by transfection of HRG cDNA into the erbB-2 overexpressing breast cancer cell line, SKBr-3. We showed that the enforced expression of HRG in SKBr-3 cells induces dramatic morphological changes and pronounced inhibition of anchorage-dependent and -independent growth. Most SKBr-3/HRG-transfected (SK/HRG) cells exhibited about 15-fold increase in size and persisted as multinucleated cells with extended flattened vacuole-filled cytoplasm with reduced cell attachment. The growth suppression of SK/HRG cells was accompanied by a reduction in S phase, the presence of a G2-M cell cycle delay, and an increase in DNA aneuploid components. In addition, DNA fragmentation assays showed that HRG induced apoptosis of SKBr-3 cells. In contrast, while HRG treatment of other erbB-2 overexpressing breast cancer cell lines led to growth arrest and cell detachment, it did not induce apoptotic features. Thus, this study demonstrates that while growth arrest and cell detachment are general effects of HRG towards erbB-2 overexpressing cells, the ability of HRG to induce apoptosis is a phenomenon confined to selective cells including SKBr-3 cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536169     DOI: 10.3892/ijo.15.5.883

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Neuregulin mediates F-actin-driven cell migration through inhibition of protein kinase D1 via Rac1 protein.

Authors:  Heike Döppler; Ligia I Bastea; Tim Eiseler; Peter Storz
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

2.  CCN1, a candidate target for zoledronic acid treatment in breast cancer.

Authors:  Ingrid Espinoza; Hong Liu; Robert Busby; Ruth Lupu
Journal:  Mol Cancer Ther       Date:  2011-03-10       Impact factor: 6.261

3.  Cellular effects of HER3-specific affibody molecules.

Authors:  Lovisa Göstring; Magdalena Malm; Ingmarie Höidén-Guthenberg; Fredrik Y Frejd; Stefan Ståhl; John Löfblom; Lars Gedda
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

4.  Identification of Potential Anticancer Activities of Novel Ganoderma lucidum Extracts Using Gene Expression and Pathway Network Analysis.

Authors:  Chi H J Kao; Karen S Bishop; Yuanye Xu; Dug Yeo Han; Pamela M Murray; Gareth J Marlow; Lynnette R Ferguson
Journal:  Genomics Insights       Date:  2016-02-16

5.  Computational Analysis of Specific MicroRNA Biomarkers for Noninvasive Early Cancer Detection.

Authors:  Tianci Song; Yanchun Liang; Zhongbo Cao; Wei Du; Ying Li
Journal:  Biomed Res Int       Date:  2017-03-05       Impact factor: 3.411

6.  Stevioside mediated chemosensitization studies and cytotoxicity assay on breast cancer cell lines MDA-MB-231 and SKBR3.

Authors:  Noopur Khare; Sheela Chandra
Journal:  Saudi J Biol Sci       Date:  2018-10-09       Impact factor: 4.219

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.